Impact of Social Disparities on 5-Year Survival Rates in Pediatric Hematologic Malignancies

Victor Chalfant1, Carlos Riveros2, Allison Bechtel3

  • 1Division of Urology, Southern Illinois University School of Medicine, Springfield, IL.

Insights

Children with acute lymphoblastic leukemia (ALL) from deprived areas have worse survival rates. The social deprivation index (SDI) highlights these disparities, suggesting social programs could improve outcomes.

Area of Science:

  • Pediatric Oncology
  • Social Determinants of Health
  • Health Disparities

Background:

  • Socioeconomic disparities significantly impact survival rates in pediatric hematologic malignancies.
  • Social determinants of health (SDH) can lead to worse outcomes and long-term effects in children.
  • The social deprivation index (SDI) quantifies SDH using county-level data.

Purpose of the Study:

  • To analyze survival outcomes in pediatric hematologic malignancies.
  • To stratify survival based on area deprivation using the SDI.
  • To identify disparities in pediatric cancer care.

Main Methods:

  • Retrospective cohort study (1975-2016) using the SEER registry.
  • Included pediatric patients (≤18 years) with leukemia or lymphoma.
  • Patients categorized by cancer subtype and SDI quartiles (Q1=least deprived, Q4=most deprived).

Main Results:

  • 38,318 patients included in the analysis.
  • Survival outcomes stratified by area deprivation for acute lymphoblastic leukemia (ALL).
  • Patients with ALL in the most deprived areas (Q4) showed a ~3% higher 5-year mortality (overall and cancer-specific) compared to the least deprived (Q1).

Conclusions:

  • Disparities in pediatric ALL survival highlight a critical area for quality improvement.
  • Social programs informed by metrics like SDI may enhance survival outcomes.
  • Addressing socioeconomic factors is crucial for improving pediatric cancer care.
Abstract

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
357
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
339
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
200
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.3K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.4K